Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zymeworks Inc. - Common Stock
(NQ:
ZYME
)
24.69
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zymeworks Inc. - Common Stock
< Previous
1
2
3
4
Next >
Zymeworks Announces Participation in Upcoming Investor Conferences
March 24, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
↗
March 19, 2026
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Via
The Motley Fool
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
March 18, 2026
Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
March 17, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Inc (NASDAQ:ZYME) Posts Wider Q4 Loss Despite Strategic Progress and Royalty Deal
↗
March 02, 2026
Via
Chartmill
ZYMEWORKS INC (NASDAQ:ZYME) Fits the Minervini Trend Template with High Growth Momentum
↗
January 01, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
March 09, 2026
Via
Chartmill
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
March 09, 2026
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading...
Via
Benzinga
Topics
Stocks
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript
↗
March 02, 2026
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
March 02, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
March 02, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 02, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
↗
February 22, 2026
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
February 12, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
January 27, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
January 12, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Outlines Strategic Priorities and Outlook for 2026
January 11, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
January 06, 2026
From
Zymeworks Inc.
Via
GlobeNewswire
Which stocks are moving after the closing bell on Tuesday?
↗
December 02, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Zymeworks Announces Participation in Upcoming Conferences
December 02, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
November 24, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes
↗
November 24, 2025
Strong new Phase 3 Ziihera data boosted confidence in upcoming regulatory milestones.
Via
Stocktwits
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
From
MarketNewsUpdates.com
Via
GlobeNewswire
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
November 18, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
November 18, 2025
Via
Benzinga
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
November 18, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
November 18, 2025
From
Zymeworks Inc.
Via
GlobeNewswire
Let's take a look at the stocks that are in motion in today's session.
↗
November 17, 2025
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
↗
November 17, 2025
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
November 17, 2025
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
